In Segment C, members will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment right until ailment progression or perhaps the members are not able to tolerate the study drugs. Probable new methods for that analysis and treatment of AML. (A) https://clinicaltrialrecruitmentf67902.bloguerosa.com/31219175/the-2-minute-rule-for-abbv-744-and-other-brd4-inhibitors-comparison